Kang JeenJoo 4
4 · Tenaya Therapeutics, Inc. · Filed Aug 4, 2021
Insider Transaction Report
Form 4
Kang JeenJoo
Director
Transactions
- Conversion
Common Stock
2021-08-03+12,500→ 25,000 total - Conversion
Series A Preferred Stock
2021-08-03−12,500→ 0 totalExercise: $0.00→ Common Stock (12,500 underlying)
Footnotes (1)
- [F1]Each share of Series A Preferred Stock automatically converted into one share of common stock immediately prior to the completion of the Issuer's initial public offering, and had no expiration date.